AbbVie (ABBV) Highlights Robust Gastroenterology Portfolio with New Data in Crohn's Disease and Ulcerative Colitis at the UEG Week
AbbVie (NYSE: ABBV) today revealed the spectrum of new data from studies of risankizumab (SKYRIZI®) in Crohn's disease and upadacitinib (RINVOQ®) in ulcerative colitis and Crohn's disease that will be presented as live presentations and e-Posters at the United European Gastroenterology (UEG) Week 2022, October 8-11 in Vienna and online. In total, AbbVie is presenting 17 abstracts across a broad range of studies in inflammatory bowel disease (IBD).
"With two decades of world-class science and an unwavering commitment to patients, we continue to advance research within our robust gastro portfolio with the goal of positively impacting the lives of people living with inflammatory bowel disease," said Chiedzo Mpofu, MBChB, Ph.D., vice president, Global Medical Affairs, Immunology, AbbVie. "Our data at UEG Week 2022 reinforce our dedication to innovation and partnership with the gastroenterology community to help address a wide range of patient needs and investigate diverse solutions to help advance standards of care for IBD patients."
Key data to be presented include:
- Final analyses from the U-ACHIEVE study evaluating the efficacy and safety of RINVOQ as a maintenance therapy in moderately to severely active ulcerative colitis
- Analyses on symptomatic improvements and endoscopic outcomes in patients receiving risankizumab as an induction and maintenance therapy compared to placebo
- Primary results from the 12-week U-EXCEL induction study on the efficacy and safety of upadacitinib induction therapy in patients with moderate to severe Crohn's disease who had inadequate response or intolerance to conventional or biologic therapy
- Results from the 52-week maintenance study, FORTIFY, on the efficacy and tolerability of subcutaneous risankizumab in patients with moderate to severe Crohn's disease who had delayed response to 12 weeks of risankizumab induction therapy
- Quantitative data from the Determinants, Incidence and Consequences of Corticosteroid Excess (DICE) study, reporting on the incidence and consequences of corticosteroid use in IBD patients
* The use of upadacitinib and risankizumab are investigational in Crohn's disease in the European Union.
AbbVie abstracts in the UEG Week 2022 program include:
Abstract Title | Session Details (All Times CEST) |
Risankizumab / Crohn's Disease | |
Induction and Maintenance Treatment with Risankizumab Leads to Symptomatic Relief in Patients with Moderate to Severe Crohn's Disease | e-Poster Presentation P0437 Sunday, Oct 9 9 a.m. |
Fatigue Improvement Correlates with Reductions in Work Productivity Impairment and Related Indirect Cost in Patients with Crohn's disease: Post Hoc Analysis of Two Phase 3 Risankizumab Induction Trials | e-Poster Presentation P0980 Sunday, Oct 9 9 a.m. |
Baseline and Early Predictors of Response to Risankizumab Induction and Maintenance Treatment in Patients with Moderate to Severe Crohn's Disease | Live Moderated Poster MP442 Monday, Oct 10 14:06 – 14:12 p.m. |
52-Weeks Risankizumab Subcutaneous Maintenance Dosing is Efficacious and Well Tolerated in Patients with Moderate to Severe Crohn's Disease Who Had Delayed Response to 12-Weeks IV Risankizumab Induction | Live Oral Presentation OP126 Monday, Oct 10 14 – 14:12 p.m. |
Clinical and Endoscopic Improvements with Risankizumab Induction and Maintenance Dosing Versus Placebo are Observed Irrespective of Number of Prior Failed Biologics | Live Oral Presentation OP128 Monday, Oct 10 14:24 – 14:36 p.m. |
Upadacitinib / Ulcerative Colitis | |
Efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis receiving 16 weeks' extended induction treatment followed by 52 weeks' maintenance treatment in the U-ACHIEVE/U-ACCOMPLISH trials | e-Poster Session P0440 Sunday, Oct 9 9 a.m. |
Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active ulcerative colitis: Final results from the Phase 3 U-ACHIEVE Maintenance study | Live Oral Presentation OP001 Sunday, Oct 9 13:55 – 14:07 p.m. |
Benefit-risk assessment of upadacitinib treatment in patients with moderately to severely active ulcerative colitis | Live Moderated Poster MP243 Monday, Oct 10 11:12 – 11:18 a.m. |
Matching-Adjusted Indirect Comparison of Upadacitinib Versus Vedolizumabas Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis | Live Moderated Poster MP244 Monday, Oct 10 11:18 – 11:24 a.m. |
Benefits of high versus low dose upadacitinib as maintenance treatment in ulcerative colitis patients who were responders to 8-week induction with upadacitinib: Results from the U-ACHIEVE phase 3 maintenance trial | Live Oral Presentation OP197 Tuesday, Oct 11 11:24 – 11:36 a.m. |
Symptoms and Laboratory Values as Proxies for Endoscopic and Histologic Clinical Endpoints in Ulcerative Colitis: A Mediation Analysis Based on Upadacitinib Phase 3 Induction Trials | Live Moderated Poster MP409 Tuesday, Oct 11 11:48 – 11:54 a.m. |
Efficacy of Upadacitinib Dose Escalation in Phase 3 Long-term Extension Ulcerative Colitis Study | Live Oral Presentation OP199 Tuesday, Oct 11 11:48 – 12:00 p.m. |
Impact of Inflammatory Burden on Efficacy of Upadacitinib Maintenance Therapy in Ulcerative Colitis: Results from the Phase 3 U-ACHIEVE Study | Live Moderated Poster MP441 Tuesday, Oct 11 14 – 14:06 p.m. |
Upadacitinib / Crohn's Disease | |
Efficacy and Safety of Upadacitinib Induction Therapy in Patients with Moderately to Severely Active Crohn's Disease: Results from a Randomized Phase 3 U-EXCEL Study | Live Oral Presentation OP219 Monday, Oct 10 14:36 – 14:48 p.m. |
Disease State Abstracts / Inflammatory Bowel Disease | |
Steroid use in a high proportion of IBD patients – first results from the German cohort of the IBD-DICE study | e-Poster Presentation P0436 Sunday, Oct 9 9 a.m. |
Patient-reported burden of corticosteroid use in inflammatory bowel disease in the UK: results from the Determinants, Incidence and Consequences of Corticosteroid Excess (DICE) impact questionnaire | Live Oral Presentation OP107 Monday, Oct 10 11:12 – 11:24 a.m. |
Patterns of corticosteroid exposure and excess in inflammatory bowel disease: Results from the Determinants, Incidence and Consequences of Corticosteroid Excess (DICE) online monitoring tool | Live Moderated Poster MP110 Sunday, Oct 9 15:54 – 16 p.m. |
The full scientific program for the UEG Week 2022 is available here.
Risankizumab (SKYRIZI) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.